Glycoprotein Ilb/IIIa inhibitor

Deshmukh VR, Fiorella DJ, Albuquerque FC, Frey J, Flaster M, Wallace RC, Spetzler RF, McDougall CG. Intra-arterial thrombolysis for acute ischemic stroke preliminary experience with platelet glycoprotein Ilb/IIIa inhibitors as adjunctive therapy. Neurosurgery 2005 56 46-54 [discussion 54 5]. [Pg.95]

Cannon C, Weintraub W, Demopoulos L, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with Glycoprotein Ilb/IIIa inhibitor Tirofiban. N Engl J of Med 2001 344 1879-1887. [Pg.82]

Safety and efficacy with platelet inhibitors other than aspirin (e.g, glycoprotein Ilb/IIIa inhibitors) not established... [Pg.149]

Drug interactions Caution is called for when administering tenecteplase with drugs that affect platelet function such as aspirin, dipyridamole, clopidogrel, and glycoprotein Ilb/IIIa inhibitors. Administration of tenecteplase before, during, or after any of these drugs may increase the risk of... [Pg.267]

Topol EJ, Moliterno DJ, Hermann HC, Powers ER, et al. 2001. Comparison of two platelet glycoproteins Ilb/IIIa inhibitors, Tirofiban and abciximab, for the prevention of ischemic events with precutaneous coronary revascularization. NEJM. 344 1888-1894. [Pg.126]

Collet, J.-P., Montalescot, G., Lesty, C., and Weisel, J. W. (2002). A structural and dynamic investigation of the facilitating effect of glycoprotein Ilb/IIIa inhibitors in dissolving platelet-rich clots. Circ. Res. 90, 428-434. [Pg.287]

Anne G, Gruberg L. Platelet glycoprotein Ilb/IIIa inhibitors during percutaneous coronary interventions a pharmacological and clinical review. Expert Opin Pharmacother. 2004 5 335-348. [Pg.363]

Boersma E, Westerhout CM. Intravenous glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes lessons from recently conducted randomized clinical trials. Curr Opin lnvestig Drugs. 2004 5 313-319. [Pg.363]

Platelet physiology and the rationale for glycoprotein Ilb/IIIa inhibitors... [Pg.41]

Randomized clinical trials evaluating glycoprotein Ilb/IIIa inhibitors in different clinical settings. [Pg.42]

Variability of glycoprotein Ilb/IIIa inhibitor treatment effect in coronary intervention versus medical management... [Pg.46]

When should glycoprotein Ilb/IIIa inhibitors be stopped prior to coronary artery bypass graft ... [Pg.52]

Cook JJ, Holahan MA, Lyle EA et al. (1996) Nonpeptide glycoprotein Ilb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther 278 62-73... [Pg.314]

The mean age of patients who died was 69 years and 47% of the deaths were in women. All of the deaths that were deemed to be definitely or probably associated with glycoprotein Ilb/IIIa inhibitors were associated with excessive bleeding, most often in the nervous system. [Pg.6]

In another case of profound thrombocytopenia after abciximab there was a delayed onset (6 days after therapy) (22). The authors speculated that preceding treatment with methylprednisolone may have delayed the onset of thrombocytopenia.The mechanism of severe thrombocjdopenia associated with abciximab is unclear. Further administration should be avoided, but other glycoprotein Ilb/IIIa inhibitors (eptifibatide and tirofiban)... [Pg.6]

Ah A, Hashem M, Rosman HS, Kazmouz G, Gardin JM, Schrieber TL. Use of platelet glycoprotein Ilb/IIIa inhibitors and spontaneous pulmonary hemorrhage. J Invasive Cardiol 2003 15(4) 186-8. [Pg.7]

Brown DL. Deaths associated with platelet glycoprotein Ilb/IIIa inhibitor treatment. Heart 2003 89(5) 535-7. [Pg.7]

Drotrecogin alfa should be used with care in patients receiving heparin, thrombolytic drugs, oral anticoagulants, glycoprotein Ilb-IIIa inhibitors, and aspirin or other antiplatelet drugs (6). [Pg.267]

Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes A meta-analysis of all major randomised clinical trials. Eur Heart J 2002 23 1408-1411. [Pg.317]

Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein Ilb/IIIa inhibitor eptifibatide. Circulation 2003 107(2) 238-44. [Pg.41]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...